Evogene Ltd.

Foreign Filer Report • Mar 6, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2025

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On March 6, 2025, Evogene Ltd. ("Evogene") announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") and is incorporated herein by reference.

Evogene is holding a conference call on March 6, 2025 to discuss its quarterly results for the quarter ended December 31, 2024 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.

The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission ("SEC") File Nos. 333-253300 and 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443 and 333-203856) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: March 6, 2025

By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Reports Fourth Quarter and Full Year 2024 Financial Results.
99.2	Slide presentation for conference call of Evogene held on March 6, 2025, discussing Evogene's quarterly financial results for the fourth quarter of 2024.

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Conference call and webcast: today, March 6, 2025, 9:00 am ET

Financial Highlights:

• ◾ In the year 2024, total revenues reached approximately \$8.5 million compared to approximately \$5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.
• ◾ In Q4 2024, total revenues reached approximately \$1.6 million compared to approximately \$0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.
• ◾ Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In Q4 2024, Casterra delivered ~76 tons, while in February 2025 alone, the company already delivered ~250 tons of castor seeds.
• ◾ During 2024, Casterra delivered to its partner a total of ~215 tons of castor seeds, while in February 2025, Casterra already delivered ~250 tons. This reflects solving the bottle neck in seed production Casterra previously faced, that caused a delay in the delivery schedule and consequent price adjustments. Casterra expects to continue delivering castor seeds mainly from its existing inventory (~400 tons) to its partners throughout 2025, based on a new schedule and new orders to be received – some replacing previous 2023 orders.
• ◾ In the year 2024, total R&D expenses were approximately \$16.6 million compared to \$20.8 million in the previous year. In Q4 2024 total R&D expenses were approximately \$3.4 million compared to \$5.5 million in Q4 2023. These decreases are mainly due to the end of Canonic's activity in Q2 2024 and decrease in Lavie Bio's, Biomica's and Evogene's R&D activity mainly in Q4 2024.
• ◾ During Q4 2024 and the beginning of 2025, Evogene established an expense reduction plan, to better align with its strategic goals, leading to a reduction of ~30% in headcount, to be completed by the end of Q1 2025.
• ◾ In the year 2024, total G&A expenses were approximately \$7.4 million compared to \$6.1 million in the previous year. G&A expenses in the year 2024 included one-time expenses of \$1.5 million resulting from Evogene's fundraising and an allowance for a doubtful debt of one of Casterra's seed suppliers.
• ◾ Cash usage for 2024, without Biomica and Lavie Bio, was approximately \$10.4 million compared to \$12.5 million in 2023.

Rehovot, Israel – March 6, 2025 – Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the fourth quarter and full year period ended December 31, 2024.

Mr. Ofer Haviv, Evogene's President and CEO , stated: "Today Evogene announced a change in the Chair position of its Board. I am pleased to welcome Mr. Nir Nimrodi as the new Chairperson of the Board and would like to express my gratitude to Ms. Sarit Firon for her invaluable contributions as Chairperson, I am pleased that she will continue to support Evogene in her role as a board member."

"2024 was a year of topline growth, reduction in cash use and value creation. We expect this trend to continue. I would like to share with you Evogene's prospects for the near future", Mr. Haviv continued. "Evogene intends to direct its efforts by focusing further on the use of our ChemPass AI tech-engine in the field of AI powered drug discovery. We plan to enhance ChemPass AI tech-engine's competitive advantage for the pharma market segment and expect these efforts to manifest in collaborations for small-molecule drug discovery, with bio-tech companies and academic institutions. I hope we'll be able to announce such collaborations later this year. With respect to MicroBoost AI and GeneRator AI we intend to continue the support and development of these tech-engines based on the needs of our subsidiaries, with their funding."

"With regard to Evogene's subsidiaries our intention is to focus on creating exit events for part of our subsidiaries. An exit event is expected to inject funds to further support Evogene's activities. In addition, we plan to strengthen Casterra's position as a profitable world leader in the castor oil market. Since Evogene holds 100% of Casterra we intend to use its profits to support Evogene's activities, as well. Last, Evogene will also support subsidiaries' efforts in their strategic fundraising activities. Part of the funds will be used by the subsidiaries to finance the development of Evogene's tech-engines according to their needs."

"These strategic guidelines are expected to strengthen Evogene's financial position. Through focus on a single engine and implementation of our expense reduction plan, we expect to substantially lower expenses, and through exit events, dividends, and technology license payments, we anticipate enhancing Evogene's financials", Mr. Haviv concluded.

Subsidiaries' 2025 Targets:

Casterra Ag Ltd. – focuses on developing integrated solutions for large-scale castor bean farming, utilizing GeneRator AI tech-engine.

• Increase castor seeds revenue in Africa with initial sales in Brazil and additional territories.
• Initiate PoC trials for grain farming for oil production, with a tier 1 partner in Kenya or Brazil.
• Develop new varieties addressing market needs; advance at least 2 new lines to the pre-commercial phase.
• Develop a solution for reducing ricin quantity in meal, to be used as organic fertilizer.
• Strengthen and improve seed production facilities in Kenya and Brazil.

Lavie Bio Ltd. – a leading ag-biologicals company that develops microbiome-based, novel bio-stimulant and bio-pesticide products, utilizing Evogene's MicroBoost AI tech-engine.

• Engage in a new collaboration agreement for fungicides (LAV311, LAV321).
• Increase Yalos® revenue with initial sales in soybean.
• Achieve R&D milestones in ICL collaboration toward commercial agreement.
• Achieve R&D milestones in Corteva collaboration toward licensing agreement.

AgPlenus Ltd. – specializes in developing novel and sustainable crop protection products, utilizing Evogene's ChemPass AI tech-engine.

• Achieve second milestone in Corteva collaboration agreement.
• Execute Bayer herbicide collaboration according to workplan.
• Discover and advance 2-3 small molecules (hits) with new MoAs in Zymoseptoria program.
• Engage in a new collaboration agreement for fungicide (Zymoseptoria).

Biomica Ltd. – a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, utilizing Evogene's MicroBoost AI tech-engine.

• Complete Phase 1 study in oncology program; obtain full results and additional supporting clinical data.
• Submit an IND application to the US FDA and obtain FDA approval for the Phase 2 study.
• Obesity and Longevity programs: complete discovery and in-vitro validations; seek partners for both programs.

Financial Highlights:

Cash Position: As of December 31, 2024, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately \$15.3 million. The consolidated cash usage during the fourth quarter of 2024 was approximately \$4.6 million. Excluding Lavie Bio and Biomica, Evogene and its other subsidiaries used approximately \$1.5 million in cash during the fourth quarter of 2024. Cash usage for 2024, excluding Lavie Bio and Biomica, was approximately \$10.4 million, marking a notable 17% decrease from approximately \$12.5 million in 2023.

Revenue: Revenues for the 12 months of 2024 were approximately \$8.5 million, an increase from approximately \$5.6 million in the same period the previous year. This growth was primarily driven by revenues recognized from AgPlenus's new collaboration with Bayer and increased Casterra's revenues from the supply of castor seeds during the period. Revenues for the fourth quarter of 2024 were approximately \$1.6 million, compared to approximately \$0.6 million in the same period the previous year. The increase was mainly attributable to the increase in Casterra's seed sales and the collaboration with Bayer, as mentioned above.

R&D Expenses: Research and development expenses, net of non-refundable grants, for the 12 months of 2024 were approximately \$16.6 million, a significant decrease from approximately \$20.8 million in the 12 months of 2023. The decrease in expenses is mainly due to the cease of Canonic's activities and a decrease in certain development expenses in Biomica, Evogene and Lavie Bio as compared to the same period the previous year. Research and development expenses, net of non-refundable grants, for the fourth quarter of 2024 were approximately \$3.4 million, and decreased as compared to approximately \$5.5 million in the same period in the previous year. The decrease is mainly attributable to decreased expenses in Lavie Bio, Biomica, Evogene and the cease of Canonic's operations as mentioned above.

Sales and Marketing Expenses: Sales and Marketing expenses for the 12 months of 2024 were approximately \$3.4 million, a slight decrease from approximately \$3.6 million in the same period in the previous year. Sales and Marketing expenses for the fourth quarter of 2024 were approximately \$0.7 million, a slight decrease from approximately \$1.0 million in the same period in the previous year. The decrease is mainly due to the cease of Canonic's activities.

General and Administrative Expenses: General and administrative expenses for the 12 months of 2024 increased to approximately \$7.4 million from approximately \$6.1 million in the same period of the previous year. The increase is mainly attributable to expenses recorded in Casterra due to a provision on a doubtful debt of a seed supplier and transaction costs related to Evogene's fundraising that occurred in August 2024, totaling approximately \$1.5 million. General and administrative expenses for the fourth quarter of 2024 increased slightly to approximately \$1.4 million compared to approximately \$1.2 million in the same period of the previous year.

Other Expenses: The decision to cease Canonic's operations in the first half of 2024 resulted in other expenses of approximately \$0.5 million, mainly due to impairment of fixed assets in the first quarter of 2024.

Operating Loss: The operating loss for the 12 months of 2024 was approximately \$22.2 million, a decrease from approximately \$26.5 million in the same period of the previous year, mainly due to increased revenues and decreased research and development expenses, offset by increased general and administrative expenses and other expenses, as mentioned above. The operating loss for the fourth quarter of 2024 was approximately \$4.6 million, a decrease from approximately \$7.6 million in the same period of the previous year, mainly due to increased revenues and decreased research and development expenses as mentioned above.

Financing Income / Expenses: Financing income, net for the 12 months of 2024 was approximately \$4.2 million, compared to approximately \$0.5 million in the same period of the previous year. Financing income, net for the fourth quarter of 2024 was approximately \$4.6 million, compared to approximately \$0.3 million in the same period of the previous year. The increase in financial income, net, during the 12-month period and the fourth quarter of 2024 as compared to the respective periods of 2023 was mainly associated with accounting treatment of pre-funded warrants and warrants issued in August 2024 fund raising. Pre-funded warrants and warrants were classified as a liability on the consolidated statements of financial position, were initially recorded at fair value and subsequently remeasured at each reporting period using the Black - Scholes option pricing model. As a result, during 2024 the Company recorded net financial income, related to pre-funded warrants and warrants of approximately \$3.4 million.

Net Loss: The net loss for the 12 months of 2024 was approximately \$18.1 million, compared to approximately \$26.0 million in the same period of the previous year. The net loss for the fourth quarter of 2024 was approximately \$5 thousand, compared to approximately \$7.3 million in the same period of the previous year. The \$7.9 million decrease in net loss for the 12 months of 2024 as compared to the 12 months of 2023 was primarily due to increased revenues, decreased research and development expenses and increased financial income, net related to warrants, offset by increased general and administrative expenses as mentioned above. The \$7.3 million decrease in net loss for the fourth quarter of 2024 as compared to the fourth quarter of 2023 was primarily due to increased revenues, decreased research and development expenses and increased financial income, net related to warrants as mentioned above.

For the financial tables click here.

Conference Call & Webcast Details: Thursday, March 6, 2025. 9:00 AM EST 4:00 PM IDT

To join the Zoom conference, please register in advance here

Or join via audio

US: +1 507 473 4847 or +1 564 217 2000 or +1 646 558 8656 or +1 646 931 3860

Israel: +972-3-9786688

Webinar ID: 870 4653 3198

More International numbers

Webcast & Presentation link available at:

https://evogene.com/investor-relations/

About Evogene Ltd.

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:

• Biomica Ltd. (www.biomicamed.com) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
• Lavie Bio (www.lavie-bio.com) developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
• AgPlenus Ltd. (www.agplenus.com) developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI;
• Casterra Ag (www.casterra.co) developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.

For more information, please visit: www.evogene.com.

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss Evogene's success with creating collaborations for small-molecule drug discovery, with mid-size bio-tech companies and academic institutions, creating exit events for part of Evogene's subsidiaries, continuance of delivering castor seeds to its partners throughout 2025 and the subsidiaries' success in their strategic fundraising activities. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investors Relations Contact:

Email: ir@evogene.com

Tel: +972-8-9311901

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

		December 31, 2024	December 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	\$	15,301	\$ 20,772
Short-term bank deposits		10	10,291
Trade receivables		1,091	357
Other receivables and prepaid expenses		2,064	2,973
Deferred expenses related to issuance of warrants		3,039	-
Inventories		1,819	76
		23,324	34,469
LONG-TERM ASSETS:
Long-term deposits and other receivables		12	28
Investment accounted for using the equity method		82	-
Right-of-use-assets		2,447	980
Property, plant and equipment, net		1,804	2,455
Intangible assets, net		12,195	13,169
		16,540	16,632
	\$	39,864	\$ 51,101
CURRENT LIABILITIES:
Trade payables	\$	1,228	\$ 1,785
Employees and payroll accruals		1,869	2,537
Lease liability		589	853
Liabilities in respect of government grants		323	388
Deferred revenues and other advances		360	362
Warrants and pre-funded warrants liability		2,876	-
Convertible SAFE		10,371	-
Other payables		1,079	1,019
		18,695	6,944
LONG-TERM LIABILITIES:
Lease liability		1,914	285
Liabilities in respect of government grants		4,327	4,426
Deferred revenues and other advances		90	393
Convertible SAFE		-	10,368
		6,331	15,472
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.2 par value:
Authorized – 15,000,000 ordinary shares; Issued and outstanding – 6,795,589 shares on December 31, 2024 and 5,079,313 (*) shares on
December 31, 2023		363	286
Share premium and other capital reserve		272,257	269,353
Accumulated deficit		(274,071)	(257,586)
Equity attributable to equity holders of the Company		(1,451)	12,053
Non-controlling interests		16,289	16,632
Total equity		14,838	28,685
	\$	39,864	\$ 51,101

(*) Shares and per shares amounts have been retroactively adjusted to reflect the reserve stock split

U.S. dollars in thousands (except share and per share amounts)

	Year ended December 31,			Three months ended December 31,
		2024		2023		2024		2023
Revenues	\$	8,511	\$	5,640	\$	1,611	\$	578
Cost of revenues		2,683		1,692		755		398
Gross profit		5,828		3,948		856		180
Operating expenses (income):
Research and development, net		16,648		20,777		3,401		5,545
Sales and marketing		3,425		3,611		650		1,033
General and administrative		7,441		6,068		1,372		1,230
Other expenses		524		-		-		-
Total operating expenses, net		28,038		30,456		5,423		7,808
Operating loss		(22,210)		(26,508)		(4,567)		(7,628)
Financing income		7,546		1,486		4,726		358
Financing expenses		(3,342)		(965)		(144)		(71)
Financing income (expenses), net		4,204		521		4,582		287
Share of loss of an associate		39		-		13		-
Gain (loss) before taxes on income		(18,045)		(25,987)		2		(7,341)
Taxes on income (tax benefit)		9		(33)		7		(4)
Loss	\$	(18,054)	\$	(25,954)	\$	(5)	\$	(7,337)
Attributable to:
Equity holders of the Company		(16,485)		(23,879)		427		(6,601)
Non-controlling interests		(1,569)		(2,075)		(432)		(736)
	\$	(18,054)	\$	(25,954)	\$	(5)	\$	(7,337)
Basic and diluted loss per share, attributable to equity holders of the Company (*)	\$	(2.89)	\$	(5.20)	\$	0.06	\$	(1.30)
Weighted average number of shares used in computing basic and diluted loss per share (*)		5,697,245		4,589,386		6,795,589		5,079,313

(*) Shares and per shares amounts have been retroactively adjusted to reflect the reserve stock split.

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Year ended December 31,			Three months ended December 31,
	2024	2023	2024	2023
Cash flows from operating activities:
Loss	\$ (18,054)	\$ (25,954)	\$ (5)	\$ (7,337)
Adjustments to reconcile loss to net cash used in operating activities:
Adjustments to the profit or loss items:
Depreciation and amortization	1,530	1,641	348	418
Amortization of intangible assets	974	971	245	245
Share-based compensation	1,795	1,877	317	113
Revaluation of convertible SAFE	3	254	51	77
Net financing income	(689)	(666)	(986)	(460)
Loss (gain) from sale of property, plant and equipment	524	(26)	-	-
Excess of initial fair value of pre-funded warrants over transaction proceeds	2,684	-	-	-
Amortization of deferred expenses related to issuance of warrants	471	-	334	-
Remeasurement of pre-funded warrants and warrants	(6,529)	-	(4,589)	-
Associated Company loss share	39	-	13	-
Taxes on income (tax benefit)	9	(33)	7	(4)
	811	4,018	(4,260)	389
Changes in asset and liability items:
Decrease (increase) in trade receivables	(734)	(9)	499	988
Decrease (increase) in other receivables	925	(1,445)	324	(1,025)
Decrease (increase) in inventories	(1,743)	490	(363)	37
Decrease in deferred taxes	-	94	-	94
Increase (decrease) in trade payables	(596)	742	(62)	563
Increase (decrease) in employees and payroll accruals	(668)	550	(420)	478
Increase (decrease) in other payables	62	(534)	(77)	(67)
Decrease in deferred revenues and other advances	(559)	(288)	(463)	(478)
	(3,313)	(400)	(562)	590
Cash received (paid) during the period for:
Interest received	934	905	288	472
Interest paid	(67)	(115)	(11)	(23)
Taxes paid	(11)	(31)	(11)	(16)
Net cash used in operating activities	\$ (19,700)	\$ (21,577)	\$ (4,561)	\$ (5,925)

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands
	Year ended December 31,				Three months ended December 31,
		2024 2023		2024			2023
Cash flows from investing activities:
Purchase of property, plant and equipment	\$	(626)	\$	(785)	\$	(322)	\$	(86)
Proceeds from sale of marketable securities		-		6,924		-		-
Purchase of marketable securities		-		(503)		-		-
Proceeds from sale of property, plant and equipment		58		26		-		-
Proceeds from short term bank deposits, net		10,190		(10,200)		9,080		(500)
Net cash provided by (used in) investing activities		9,622		(4,538)		8,758		(586)
Cash flows from financing activities:
Issuance of a subsidiary preferred shares to non-controlling interests		-		9,523		-		-
Proceeds from issuance of ordinary shares, pre-funded warrants and warrants		5,500		-		-		-
Proceeds from issuance of ordinary shares, net of issuance expenses		123		8,449		-		45
Repayment of lease liability		(901)		(836)		(206)		(212)
Proceeds from government grants		232		1,089		-		20
Repayment of government grants		(298)		(73)		-		-
Net cash provided by (used in) financing activities		4,656		18,152		(206)		(147)
Exchange rate differences - cash and cash equivalent balances		(49)		(245)		(7)		99
Decrease in cash and cash equivalents		(5,471)		(8,208)		3,984		(6,559)
Cash and cash equivalents beginning of the period		20,772		28,980		11,317		27,331
Cash and cash equivalents end of the period	\$	15,301	\$	20,772	\$	15,301	\$	20,772
Significant non-cash activities
Acquisition of property, plant and equipment	\$	120	\$	81	\$	120	\$	81
Increase of right-of-use-asset recognized with corresponding lease liability	\$	2,307	\$	194	\$	-	\$	59
Exercise of pre-funded warrants	\$	2,289	\$	-	\$	2,289	\$	-
Investment in affiliated Company with corresponding deferred revenues	\$	120	\$	-	\$	-	\$	-

Q 4 2 0 2 4 E A R N I N G S C A L L O F E R H A V I V | P R E S I D E N T & C E O M a r c h 0 6 , 2 0 2 5

Exhibit 99.2

FORWARD LOOKING STATEMENT

This presentation contains "forward-looking to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectation or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticle", "should", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in the we discuss our value drivers, commercialization and production efforts and timing, poduct development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expections and assumptions describe opinions about future events in roly certain rides and uncertainties which are difficult to predict and are not guarantes of future performance. Readers and affect the Company's actual results and could cause such reserially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achever may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in the mobilizations or escalation in the northern border of Irrael and those risks described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we digation or commitment to update any information contained in this presentation or to publicly release the results of any statements that may be made to reflect future events or changes in expectations. estimates, projections and assumptions

The information contained herein does not constitute a prospectus or other offering document, nor dom invitation or offer to sell, or any solicitation of any invitation or offer to pay securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or reating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners theref and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

evogene

· Nir Nimrodi, New Chairman · Financial & Business Highlights · Evogene Overview · Subsidiaries' 2025 Targets CFO Update / By Yaron Eldad

3

Q&A

CEO Update / By Ofer Haviv

Nir Nimrodi, New Chairman of the Board

Mr. Nir Nimrodi has served as Special Advisor to the Evogene board since 2020, and from September 2022 as a board member.

Mr. Nimrodi brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical, and biotechnology industries.

Mr. Nimrodi was the Chairman and CEO of Accellix Inc from June 2019 thru September 2024. Accellix aims to set a new standard in QC of Cell and Gene Therapies.

Prior to joining Accellix, Mr. Nimrodi served as the Chief Business Officer of Intrexon Corporation, a leader in synthetic biology. At Intrexon, Mr. Nimrodi held direct responsibility for all of the commercial stage enterprises. Mr. Nimrodi has led the transformation of Intrexon from an R&D organization to one with multiple products in the market, each with the potential of generating hundreds of millions of dollars annually.

Prior to Intrexon, Mr. Nimrodi has held positions with Life Technologies, Proneuron Biotechnologies, Mindsense Biosystems and Teva Pharmaceuticals.

Mr. Nimrodi holds a BA in Economics and an MBA from the Tel Aviv University.

4

CEO Update / By Ofer Haviv

• Nir Nimrodi, New Chairman
• · Financial & Business Highlights

5

· Evogene Overview

Q&A

• · Subsidiaries' 2025 Targets
• CFO Update / By Yaron Eldad

evogene -

Financial Highlights:

• · In the year 2024, total revenues reached approximately \$8.5 million compared to \$5.6 million in the year 2023. The increase in revenues in year 2024, is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.
• · In Q4 of 2024, total revenues reached approximately \$1.6 million compared to \$0.6 million in Q4 2023. The increase in revenues in Q4 2024, is mainly due to the increase in Casterra's seed sales.
• · The main reason for the lower revenue in Q4 2024, compared to expectations, is the change in the delivery schedule of Casterra's seeds from 2024 to 2025. In the entire Q4 2024, Casterra delivered ~76 tons, while in February 2025 alone, the company already delivered ~250 tons of castor seeds.
• · During 2024, Casterra delivered to its partner a total of ~215 tons of castor seeds. As stated, just in February this year, Casterra delivered ~250 tons – which reflects solving the bottle neck in seed production Casterra previously faced, that caused a delay in the delivery schedule and consequent price adjustments. Casterra is expecting to continue delivering castor seeds mainly from its existing inventory (~400 tons) to its partners throughout 2025, based on a new schedule and new orders to be received - some replacing previous 2023 orders.

Financial Highlights:

• · In the year 2024, total R&D expenses were approximately \$16.6 million compared to \$20.8 million in the year 2023. In Q4 of 2024, total R&D expenses were approximately \$3.4 million compared to \$5.5 million in Q4 2023. These decreases are mainly due to the end of Canonic's activity in Q2 2024 and a decrease in Biomica's and Lavie Bio's R&D activity mainly in Q4 2024.
• During Q4 2024 and the beginning of 2025, Evogene established an expense reduction plan, that led to a reduction in headcount which will be completed by Q1 2025 of ~30%. The effect of this plan will be reflected starting Q1 2025.
• · In the year 2024, total G&A expenses were approximately \$7.4 million compared to \$6.1 million in the year 2023. G&A expenses in 2024 included one-time expenses of approximately \$1.5 million resulting from Evogene's fundraising and an allowance for a doubtful debt of one of Casterra's seed suppliers.
• · Operating expenses in 2024 include other expenses totaling \$0.5M occurring in Q1 due to the end of Canonic's activity.

evogene --------

Business Highlights 2024 to date:

Evogene

. Oct. 2024, collaboration with Google Cloud to pioneer generative Al foundation model for novel small molecule design.

Casterra

• · During 2024, Casterra delivered to its partner ~215 tons of castor seeds, ~76 tons in Q4 2024.
• · In February 2025 Casterra delivered to its partner ~250 tons of castor seeds.
• · Casterra expects to continue supplying castor seeds during the coming months for new orders received in 2025, replacing some of the orders from 2023, mainly from existing seed inventory (~400 tons).
• · Seed production in Africa:
  • Oct. 2024, reporting key milestone in operational expansion in Q4, with completion of first shipment of over 100 tons of castor seeds grown and processed in Kenya.
  • Completion of current harvest season by Feb. 2025, supporting current and future demands.
• · Seed production in Brazil:
  • July 2024, completion of growing and harvesting season; seed shipment initiated in 2024 and continuing into 2025.
• · In Q12025 Casterra initiated PoC trials for castor grain farming in Africa and Brazil, using a new commercial growth protocol. Such grain will be used for oil production.

8

Business Highlights 2024 to date:

Lavie Bio

• · Feb. 2024, new collaboration agreement with Syngenta to discover and develop novel bio-insecticides.
• · July 2024, ICL and Lavie Bio achieved a significant milestone in their collaboration, developing yield-increasing bio-stimulants for row crops under extreme weather conditions by leveraging Al to identify over a dozen novel microbial candidates.
• Commercial expansion of Yalos® to winter wheat (July 2024) and to sybean (November 2024). Expected initial sales for soybean in spring . 2025.
• . Nov. 2024, advancement of LAV321, a bio-fungicide targeting downy mildew, to pre-commercialization, following successful field trial results.

AgPlenus

• · Feb. 2024, new collaboration agreement with Bayer to develop a new sustainable weed control solution; AgPlenus entitled to an upfront payment, ongoing research funding, milestone payments and royalties.
• · March 2024, AgPlenus achieved a milestone with Corteva, in an existing collaboration agreement for novel herbicides.
• · Feb. 2025, AgPlenus announced discovery of a new MoA for fungicides against wheat disease (Septoria tritici blotch).

Biomica

• · Phase I of the clinical study for microbiome-based therapeutic BMC128 is nearing completion, with a prolonged positive response of 5 patients, 4 of whom are still active in the study (I) patients started, In June 2024, initial results presented at the ASCO annual conference.
• · Positive feedback from the FDA following a pre-IND meeting at the beginning of 2024; IND submission is expected in Q3 2025.

evogene

CEO Update / By Ofer Haviv • Nir Nimrodi, New Chairman · Financial & Business Highlights · Evogene Overview

• · Subsidiaries' 2025 Targets
• CFO Update / By Yaron Eldad

Q&A

10

OUR VISION

PIONEER GROUNDBREAKING LIFE-SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS

OUR MISSION

WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING-EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS

WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT DISCOVERY & OPTIMIZATION

through 3 dedicated AI tech-engines

Capture the value of our Al tech-engines through diverse collaborative partnerships to accelerate life-science product development

Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene.

LICENSING & COLLABORATION | current status

LOOKING INTO 2025-2026

Evogene

• Focus on enhancing ChemPass Altech-engine's compettive advantage for the pharma market segment (ex. - building foundation model with Google Cloud).
• · Engage in collaborations with bio-tech and academia for small-molecule drug discovery, utilizing ChemPass A.
• · Continue the support and development of MicroBoost Al and GeneRator Albased on the needs of our subsidiaries, with their funding.

Evogene's Subsidiaries

• · Focus on creating exit events for Evogene with respect to part of our subsidiaries.
• · Strengthen Casterra's position as a profitable world leader in the castor oil market.
• · Support subsidiaries' efforts in their strategic fundraising activities.

Strengthening Evogene's Financial Position

• · Focusing Evogene's financial resources on a single tech engine & implementing its expense reduction plan are expected to substantially lower expenses.
• · The strategy to unlock value from our subsidiaries through exit events, dividends from profitable subsidiaries, and technology license payments is anticipated to enhance Evogene's financial position.

DRUG DEVELOPMENT BASED ON SMALL MOLECULES

evogene

DECODING BIOLOGY * 18

WHY PHARMA?

• 1. The Challenge: Discovering the right small molecule is like finding a needle in a haystack.
• 1. The Rewards: A solution offers the potential for significant financial impact.
• 1. The Al Revolution: Al enables the discovery and optimization of small molecule candidates, addressing multiple development requirements for a successful drug. This approach addresses the urgent need for novel drugs.
• 1. Early Adoption: The pharmaceutical industry is willing to invest in novel breakthrough technologies.

evogene

DECODING BIOLOGY * 19

MULTI-MILLION AGREEMENTS WITH GLOBAL PHARMA

Bayer to invest up to \$1.5 billion with 'disruptive' Recursion

Pharmaceutical - 10 November 2023

Eli Lilly, XtalPi ink \$250M deal

for Al-powered drug discovery

insitro Announces Five-Year Discovery Collaboration with Bristol

Myers Squibb to Discover and Develop Novel Treatments for

Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

insitro to Receive \$50 Million in Upfront Cash with Total Potential Deal Value Over \$2.1 Billion

Collaboration to Advance Targets and Therapeutic Candidates

AstraZeneca to Spend \$247M in Collaboration with Al Discovery Outfit Absci

December 4, 2023 | 2 min read | Tyler Patchen

Lilly Inks Up-to-\$560M Al Drug Discovery Collaboration with Atomwise

Sanofi signs \$140m small molecule discovery deal with Aqemia

The multi-year research collaboration will involve Aqemia's Al platform, with the company receiving up to \$140m from Sanofi.

evogene

By Andrea Park · May 30, 2023 10:30am

DECODING BIOLOGY 20

WHY EVOGENE?

Technology Differentiation Unique Capabilities Chem Chem De-Novo Application Generative-Al for novel small Multidisciplinary Expertise molecules (NCEs) Integrating chemistry, biology, and Al for optimized drug discovery First-in Class Foundation Model State-of-the-art Al model, developed in Al-First Approach collaboration with Google Cloud, Internal capabilities to develop enhanced de novo design propriety machine learning and deep learning algorithms Multi-Parameter Optimization Increase probability of success by derisking later phases of drug development Collaborative Partnership (efficacy, ADME, safety) Proven ability to work with partners, to translate computational predictions into Vast Screening Capability real-world drug candidates A deep learning platform leveraging a curated database of 40 billion compounds to identify the most promising candidates DECODING BIOLOGY * 21

evogene

DISCUSSIONS WITH POTENTIAL PARTNERS

evøgene

DECODING BIOLOGY * 22

CEO Update / By Ofer Haviv • Nir Nimrodi, New Chairman · Financial & Business Highlights · Evogene Overview · Subsidiaries' 2025 Targets

CFO Update / By Yaron Eldad

Q&A

23

Casterra focuses on developing integrated solutions for large-scale castor bean farming, utilizing GeneRator Al tech-engine

Main targets for 2025

• · Increase castor seeds revenue in Africa with initial sales in Brazil and additional territories.
• · Initiate POC trials for grain farming for oil production, with a tier 1 partner in Kenya or Brazil.
• Develop new varieties addressing market needs; advance at least two new lines to the pre-commercial phase.
• · Develop a solution for reducing ricin quantity in meal, to be used as organic fertilizer.
• · Strengthen and improve seed production facilities in Kenya and Brazil.

Lavie Bio, a global leader in developing next generation ag-biological products, leveraging MicroBoost Al tech-engine

Main targets for 2025

• · Engage in a new collaboration agreement for fungicides (LAV311, LAV321).
• · Increase Yalos® revenue with initial sales in soybean.
• · Achieve R&D milestones in ICL collaboration toward commercial agreement.
• · Achieve R&D milestones in Corteva collaboration toward licensing agreement.

AgPlenus specializes in developing novel and sustainable crop protection products, utilizing Evogene's ChemPass Al tech-engine

Main targets for 2025

• · Achieve 2nd milestone in Corteva collaboration agreement.
• · Execute Bayer herbicide collaboration according to workplan.
• · Discover and advance 2-3 small molecules (hits) with new MoAs in Zymoseptoria program.
• · Engage in a new collaboration agreement for fungicide (Zymoseptoria).

Biomica specializes in developing microbiome-based therapeutics for human health, utilizing Evogene's MicroBoost Al tech-engine

Main targets for 2025

• · Complete Phase 1 study in oncology program; obtain full results and additional supporting clinical data.
• · Submit IND application to the US FDA and obtain FDA approval for the Phase 2 study.
• · Obesity and Longevity programs: complete discovery & invitro validations; seek partners for both programs.

CEO Update / By Ofer Haviv • Nir Nimrodi, New Chairman · Financial & Business Highlights · Evogene Overview · Subsidiaries' 2025 Targets CFO Update / By Yaron Eldad Q&A

28

CFO UPDATE

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

	December 31, 2024		December 31, 2023
	Unaudited
CURRENT ASSETS:
Cash and cash equivalents	S	15,301	S	20,772
Short-term bank deposits		10		10,291
Trade receivables		1.091		357
Other receivables and prepaid expenses		2.064		2,973
Deferred expenses related to issuance of warrants		3,039
Inventories		1,819		76
		23,324		34,469
LONG-TERM ASSETS:
Long-term deposits and other receivables		12		28
Investment accounted for using the equity method		82
Right-of-use-assets		2,447		980
Property, plant and equipment, net		1,804		2,455
Intangible assets, net		12,195		13,169
		16,540		16,632
	S	39,864	A	51.101

ev@gene ______________________________________________________________________________________________________________________________________________________________________

• 29

CFO UPDATE

	December 31, 2024	December 31, 2023
CURRENT LIABILITIES:
Trade payables	રે 1.228	5 1.785
Employees and payroll accruals	1,869	2,537
Lease liability	589	853
Liabilities in respect of government grants	323	388
Deferred revenues and other advances	360	362
Warrants and pre-funded warrants liability	2,876
Convertible SAFE	10,371
Other payables	1,079	1,019
	18,695	6,944
LONG-TERM LIABILITIES:
Lease liability	1.914	285
Liabilities in respect of government grants	4,327	4,426
Deferred revenues and other advances	90	393
Convertible SAFE		10,368
	6.331	15,472
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.2 par value:
Authorized - 15,000,000 ordinary shares; Issued and
outstanding - 6,795,589 shares on December 31, 2024 and
5,079,313 (*) shares on December 31, 2023	363	286
Share premium and other capital reserve	272,257	269,353
Accumulated deficit	(274,071)	(257,586)
Equity attributable to equity holders of the Company	(1,451)	12,053
Non-controlling interests	16,289	16,632
Total equity	14,838	28,685
	\$ 39,864	\$ 51,101

CFO UPDATE

Evogene Financial Performance 2024 and Q4 2024

	December 31,		December 31,
	2024	2023	2024	2023
	(Unaudited)		(Unaudited)
Revenues	\$ 8,511	\$ 5,640	ર્ડ 1,611	ડ 578
Cost of revenues	2,683	1,692	રેરે	398
Gross profit	5.828	3.948	જરૂર	180
Operating expenses (income):
Research and development, net	16,648	20,777	3,401	5,545
Sales and marketing	3,425	3,611	650	1.033
General and administrative	7,441	୧.୦୧%	1,372	1,230
Other expenses	524
Total operating expenses, net	28,038	30,456	5,423	7,808
Operating loss	(22,210)	(26,508)	(4,567)	(7,628)
Financing income	7.546	1,486	4,726	358
Financing expenses	(3,342)	(962)	(144)	(71)
Financing income (expenses), net	4,204	521	4,582	287
Share of loss of an associate	39		13
Gain (loss) before taxes on income	(18,045)	(25,987)	2	(7,341)
Taxes on income (tax benefit)	9	(33)	7	(4)
Loss	\$ (18,054)	\$ (25,954)	ਟੋ (2)	\$ (7,337)
Attributable to:
Equity holders of the Company	(16,485)	(23,879)	427	(6,601)
Non-controlling interests	(1,569)	(2,075)	(432)	(736)
	\$ (18,054)	\$ (25,954)	S (2)	\$ (7,337)
Basic and diluted loss per share, attributable to equity holders of the
Company (*)	\$ (2.89)	\$ (5.20)	રે 0.06	\$ (1.30)
Weighted average number of shares used in computing basic and diluted
loss per share (*)	5,697,245	4,589,386	6,795,589	5,079,313

evogene ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

• 31

• Nir Nimrodi, New Chairman · Financial & Business Highlights · Evogene Overview · Subsidiaries' 2025 Targets CFO Update / By Yaron Eldad

32

Q&A

CEO Update / By Ofer Haviv

evogene -

THANK YOU